Moia M - Search Results

1

[Arg506 --> Gln mutation of coagulation factor V (factor V Leiden) and transient cerebral ischemia at a young age in 3 members of the same family].

Moia M, La Spina I, Padalino R, Carpenedo M. Moia M, et al. Ann Ital Med Int. 1996 Jan-Mar;11(1):17-9. Ann Ital Med Int. 1996. PMID: 8645525 Italian.

2

Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation.

Rebora P, Moia M, Carpenedo M, Valsecchi MG, Genovesi S. Rebora P, et al. Among authors: moia m. Blood Transfus. 2021 Nov;19(6):487-494. doi: 10.2450/2020.0217-20. Epub 2020 Dec 3. Blood Transfus. 2021. PMID: 33370222 Free PMC article.

3

Patient preferences and willingness to pay for different options of anticoagulant therapy.

Moia M, Mantovani LG, Carpenedo M, Scalone L, Monzini MS, Cesana G, Mannucci PM. Moia M, et al. Intern Emerg Med. 2013 Apr;8(3):237-43. doi: 10.1007/s11739-012-0844-3. Epub 2012 Aug 28. Intern Emerg Med. 2013. PMID: 22926743

4

Venous thromboembolism after laparoscopic surgery: two case reports and review of the literature.

Alatri A, Tronci M, Bucciarelli P, Moia M. Alatri A, et al. Among authors: moia m. Ann Ital Med Int. 1998 Jan-Mar;13(1):53-5. Ann Ital Med Int. 1998. PMID: 9642843 Review.

5

Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study.

Cosmi B, Palareti G, Moia M, Carpenedo M, Pengo V, Biasiolo A, Rampazzo P, Morstabilini G, Testa S. Cosmi B, et al. Among authors: moia m. Thromb Res. 2000 Nov 15;100(4):279-86. doi: 10.1016/s0049-3848(00)00323-6. Thromb Res. 2000. PMID: 11113271

6

Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different INR targets.

Sacco R, Sacco M, Carpenedo M, Moia M. Sacco R, et al. Among authors: moia m. J Thromb Haemost. 2006 Mar;4(3):688-9. doi: 10.1111/j.1538-7836.2006.01762.x. J Thromb Haemost. 2006. PMID: 16460458 Free article. Clinical Trial. No abstract available.

7

Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.

Moia M, Graziani G, Tenconi PM, Martinelli I, Ponticelli C. Moia M, et al. Ann Ital Med Int. 1997 Apr-Jun;12(2):67-71. Ann Ital Med Int. 1997. PMID: 9284597 Clinical Trial.

8

Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.

Ariëns RA, Alberio G, Moia M, Mannucci PM. Ariëns RA, et al. Among authors: moia m. Thromb Haemost. 1999 Feb;81(2):203-7. Thromb Haemost. 1999. PMID: 10063992

9

The G1691 --> A mutation of factor V, but not the G20210 --> A mutation of factor II or the C677 --> T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants.

Galli M, Finazzi G, Duca F, Norbis F, Moia M. Galli M, et al. Among authors: moia m. Br J Haematol. 2000 Mar;108(4):865-70. doi: 10.1046/j.1365-2141.2000.01964.x. Br J Haematol. 2000. PMID: 10792297 Free article.

10

Ischemic stroke in congenital (type II C) defective antithrombin III.

Martinelli I, Moia M, Arbini A, Tripodi A, Mannucci PM. Martinelli I, et al. Among authors: moia m. Int J Clin Lab Res. 1993;23(4):212-4. doi: 10.1007/BF02592311. Int J Clin Lab Res. 1993. PMID: 8123877

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters